Takeda Begins Japan Trials Of Mood, Anxiety Drugs From Denmark
This article was originally published in PharmAsia News
Takeda Pharmaceuticals says it has begun trials of the first of two drugs licensed from H. Lundbeck of Denmark to treat mood and anxiety disorders. As LuAA21004, the first of the two drugs, enters trials, Takeda plans to develop LuAA24530. The drugs have differing molecular structures and are intended to be sold along side each other. Both drugs are well into Phase II trials in Europe. (Click here for more - a subscription may be required
You may also be interested in...
President Trump on 27 March signed into law a $2.2tn COVID-19 stimulus package that provides $80m to the US Food and Drug Administration for emergency use authorization of medical products. See what FDA commissioner Stephen Hahn said about it here.
"We're particularly concerned about the health care area right now because obviously that's driving everything now," says Tennessee AG Herbert Slatery III. He and CRN CEO Steve Mister spoke with HBW Insight about regulation of the consumer health marketplace with FDA suspending inspections of facilities operated by businesses manufacturing and marketing products subject to its oversight.
In addition to our daily in-depth coverage of key events relating to the coronavirus pandemic, we’re bringing you a periodic round-up of other significant developments.